Solvotrin Therapeutics Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 22
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $8.06M
Latest Deal Amount
  • Investors
  • 8

Solvotrin Therapeutics General Information

Description

Operator of a drug development company aimed at chemical modifications of known drugs. The company focuses on optimizing established therapies, vitamins, and minerals utilizing innovative science to create products that deliver on unmet clinical needs, thereby enabling healthcare providers to improve the quality of life for patients across the world through better clinical outcomes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Hoffmann Park, Little Island
  • Cork
  • Ireland
+353 (021) 000 0000

Solvotrin Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Solvotrin Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 18-Dec-2020 $8.06M 000.00 000.00 Completed Generating Revenue
5. Later Stage VC 08-Jun-2018 000.00 0000 Completed Generating Revenue
4. Later Stage VC 01-Jan-2018 00000 00.00 Completed Generating Revenue
3. Later Stage VC 01-Jan-2017 00.000 00.000 Completed Generating Revenue
2. Grant 13-Nov-2012 $68.1K $4.81M Completed Startup
1. Later Stage VC 01-Jul-2011 $4.81M $4.81M Completed Startup
To view Solvotrin Therapeutics’s complete valuation and funding history, request access »

Solvotrin Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a drug development company aimed at chemical modifications of known drugs. The company focuses on optimizing
Drug Discovery
Cork, Ireland
22 As of 2021
000.00
00.00 0000-00-00
0000000000 0 000.00

0000000

e irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excep
000000000000000
East Rutherford, NJ
0000 As of 0000
0.00 0000-00-00
000000000000

0000000

od tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
0000 000000000
Ann Arbor, MI
00000 As of 0000
00 000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Solvotrin Therapeutics Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cambrex Private Equity-Backed East Rutherford, NJ 0000 000000000000
0000000 Private Equity-Backed Ann Arbor, MI 00000 00 000000
0000000000 000000 Corporation Ennigerloh, Germany
000000 000000 Formerly VC-backed Fremont, CA 00 00000 00000000 00000
000000 Formerly VC-backed San Diego, CA 00 000000&0
You’re viewing 5 of 9 competitors. Get the full list »

Solvotrin Therapeutics Patents

Solvotrin Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201704759-D0 Compounds and compositions for use in treating psoriasis Granted 24-Mar-2017 0000000000
GB-2560769-B Compounds and compositions for use in treating psoriasis Active 24-Mar-2017 0000000000
US-20210106576-A1 Compounds and compositions for use in treating psoriasis Pending 24-Mar-2017 0000000000
GB-2560769-A Compounds and compositions for use in treating psoriasis Granted 24-Mar-2017 0000000000
EP-3600552-A1 Compounds and compositions for use in treating psoriasis Pending 24-Mar-2017 A61K31/455
To view Solvotrin Therapeutics’s complete patent history, request access »

Solvotrin Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Pat O'Flynn Co-Founder, Chief Executive Officer and President
George Walsh Chief Financial Officer
Mark Ledwidge Ph.D Co-Founder & Vice President, Development & Strategy
John Gilmer Vice President, Research & Development & Co-Founder
To view Solvotrin Therapeutics’s complete executive team members history, request access »

Solvotrin Therapeutics Board Members (3)

Name Representing Role Since
Diarmuid Burke Solvotrin Therapeutics Board Member 000 0000
Michael Buckley Self Vice Chairman 000 0000
Peter Caldini Self Chairman 000 0000
To view Solvotrin Therapeutics’s complete board members history, request access »

Solvotrin Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Solvotrin Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
RAB Capital Asset Manager Minority 000 0000 000000 0
Anne Heraty Angel (individual) Minority 000 0000 000000 0
David Power Angel (individual) Minority 000 0000 000000 0
Ergo Corporation Minority 000 0000 000000 0
Healy Chemicals Limited Corporation Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »